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ABSTRACT
Background: There are several studies on seroprevalence of hepatitis A virus (HAV) in 
adults in the Middle East. 
Objectives: To determine seroprevalence of HAV among adult population in Fars prov-
ince, southern Iran.
Patients and Methods: In a cross-sectional study, we checked anti-HAV antibody (IgG) in 
subjects refereed to our health care centers to perform laboratory tests before getting 
married between March 2008 and March 2009. Age-specific seroprevalence was also 
determined. Some risk factors like level of education, type of residence, job, numbers 
of family members, and access to treated water were also evaluated in these partici-
pants.
Results: From 1050 subjects studied, 927 (88.2%) had ant-HAV antibody; 123 (11.8%) were 
antibody negative. Among subjects aged < 20 years, the anti-HAV seroprevalence was 
the lowest (79.3%) followed by subjects aged 20–30 years (91.3%) and those > 30 years 
(99%) (p = 0.01). 85.1% of studied individuals in urban areas had anti-HAV IgG while 
95.9% of subjects in rural regions were anti-HAV positive (p = 0.001). The seropreva-
lence of HAV antibody was significantly associated with number of family members 
(p = 0.001).
Conclusion: HAV is highly prevalent in our region especially in rural areas. It is better 
to vaccinate the children for HAV by the time they receive HBV vaccine or when they 
are five years.
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Background
Hepatitis A virus (HAV) is a RNA virus belonging to the 
family  Picornaviridae  and  is  the  most  common  cause 
of acute viral hepatitis worldwide (1). The virus is trans-
mitted  via  orofecal  route  predominantly  by  ingestion 
  Implication for health policy/practice/research/medical education: 
Studying the seroprevalence of HAV is suggested to all health policy makers, specialists in the field of infection diseases and internal 
medicine. Understanding all aspects of HAV in a country leads to make a complete plan for preventing it.
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of infected food and water or direct contact with an in-
fected person (1). This virus is more prevalent in low so-
cioeconomic societies, crowded regions and those using 
untreated water. Previously, most people were infected 
with HAV in their early childhood, spend an uncompli-
cated disease with minimal symptoms and 90 % of them 
have acquired natural immunity to this pathogen for the 
rest of their life. During recent decades and in parallel to 
improvement in health care systems among developing 
countries, the pattern of this viral infection has shifted 
from  childhood  to  adolescence  with  more  severe  and Hepat Mon. 2011;11(4):285-288
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even  life-threatening  course  (2).  Since  lots  of  infected 
individuals have mild symptoms or even remain asymp-
tomatic in the course of infection, epidemiological fea-
tures are described by serological tests (3). Three epidemi-
ological patterns of endemicity are observed throughout 
the world and are divided into “low,” “intermediate” and 
“high” and are dependent to age and level of hygiene (4). 
Several studies were conducted on the prevalence of HAV 
in Iranian children and adults, however, more studies 
seems to be required for a better understanding of the 
disease and to design preventive strategies in different 
country regions. The seroprevalence of HAV was 61.5% in 
children of Tehran and was increased in older ages (5). 
Another study in Northeast of Iran showed a seropreva-
lence rate of 86.8% among young adults (6, 7). Vaccina-
tion against HAV is not recommended routinely among 
patients in childhood based on its benign and uncom-
plicated  course.  However,  recommendations  for  adult 
vaccination remains to be elucidated in epidemiological 
studies investigating the immunity of adults against this 
virus. 
Objectives
This  study  was  conducted  to  evaluate  the  seropreva-
lence  and  risk  factors  of  HAV  virus  in  Fars  province, 
southern Iran.
Patients and Methods
Study population
Fars province, with 4.4 million population in 2007, is 
one of the largest provinces of Iran located in the South 
and Southwest of Iran. Shiraz with a population of nearly 
1.8 million is the capital of Fars province and one of the 
Iranian metropolises. Besides Shiraz, two northern cities 
of Fars province were also selected for sampling. Indi-
viduals were selected among those referred to our health 
care centers to perform screening laboratory tests before 
getting married between March 2008 and March 2009. 
All of these participants were Iranian and permanent in-
habitants of the selected areas. These subjects were from 
all socioeconomic classes and among adults from both 
sexes and thus could reflect the general adult popula-
tion of the society. Those who refused to participate were 
excluded from the study. Table 1 shows the demographic 
information of Iran, Fars and the three studied cities. 
Based on heterogeneity in the reported prevalence rates 
of HAV in previous studies, considering two genders and 
three age groups, the study sample size was estimated to 
be 1050 subjects. Sampling was made using a multi-stage 
random sampling method. 
Data collection
Using a questionnaire, epidemiological data including 
age, gender, type of residence (rural vs urban area), place 
of residence, level of education, job, number of family 
members and access to adequate treated water were col-
lected. Blood samples were obtained from all individuals 
referring to our health care centers for screening labora-
tory tests before marriage. All samples required for this 
study transferred to Gastroenterology and Hepatology 
Research Center affiliated to Shiraz University of Medical 
Science, where they were tested by experienced techni-
cians. Serum total anti-HAV (IgG) antibody levels were 
determined using DiaPro kits (Diagnostic Bioprobes srl, 
Milano, Italy).
Ethics and consent 
The study protocol was confirmed by Ethical Commit-
tee of Shiraz University of Medical Science. The protocol 
and goals of the study were described for participants 
and each gave informed written consent. The study was 
conducted in accordance with the Helsinki declaration 
(Edinburgh revision, 2000).
Age group Negative
No. (%)
Positive
No. (%)
< 20 67 (20.7%) 256 (79.3%)
20–30 55 (8.7%) 572 (91.3%)
> 30 1 (1%) 99 (99%)
Table 3. Age-specific seroprevalence of anti-HAV antibody in studied subjects
Statistical analysis
All data were expressed as mean ± SD. Categorical vari-
ables  were  compared  by  x²,  and  correlation  analyses 
were performed using Pearson’s correlation coefficient. 
A p < 0.05 was considered statistically significant. Statis-
tical analyses were performed using SPSS® 11 software for 
Windows® (SPSS, Inc., Chicago, IL, USA).
Table 1. Census data of Iran, Fars and the three studied cities (Source: Iran 
National Population and Housing Census, 2006)
Area
(km2)
Population Percent
urban
Percent
mail
Iran 1,648,195 70,495,782 68.5% 50.9%
Fras 133100 4,336,878 61.17% 50.8%
Shiraz 10688 1,711,186 77.37% 51.3%
Mamasani 6800 166,308 34.8% 49.5%
Abadeh 6052 92,959 89.4% 51.3%
City Negative
No. (%)
Positive
No. (%)
Shiraz 108 (12.4%) 762 (87.6%)
Mamasani 5 (4.1%) 115 (95.9%)
Abadeh 10 (16.7%) 50 (83.3%)
Total 123 (11.8%) 927 (88.2%)
Table 2. Seroprevalence of HAV antibody in the participantsHepat Mon. 2011;11(4):285-288
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Results
Totally, 1050 subjects were enrolled in this study. There 
were 523 (49.8%) males and 527 (50.2%) females. Eight-
hundred  and  seventy  (82.8%)  participants  were  from 
Shiraz,  120  (11.5%)  from  Mamasani,  and  60  (5.7%)  from 
Abadeh. From 1050 studied subjects, 927 (88.2%) had anti-
body against HAV and 123 (11.8%) were antibody negative. 
Seroprevalence of HAV antibody in the participants, ac-
cording to the city of residence is outlined in Table 2. The 
mean age of participants was 25 (range: 15–63) years. Par-
ticipants were categorized into three age groups: < 20, 
20–30, and >30 years. Age-specific seroprevalence of anti-
HAV antibody is shown in Table 3. Among subjects aged 
< 20 years, the anti-HAV seroprevalence was the lowest 
(79.3%); it followed by subjects aged 20–30 years (91.3%), 
and those > 30 years (99%) (p = 0.01). Table 4 shows sex-
specific distribution of anti-HAV antibody among our pa-
tients. According to the level of education, participants 
were categorized as follows: 1% of the study population 
were “uneducated;” 17.7% of subjects had a “preliminary 
education;”  2.8%  completed  third  year  of  high  school; 
55.1% of subjects had high school diploma and 23.4% had 
continued their education after diploma. Seroprevalence 
of anti-HAV antibody according to the level of education 
is shown in Table 4. All of uneducated individuals were 
found anti-HAV positive. However, there was no statisti-
cally  significant  different  in  anti-HAV  seroprevalence 
among participants with different levels of education 
(p = 0.25). Seven-hundred and twenty-nine (69%) of sub-
jects resided in urban area while 321 (31%) were from rural 
areas (Table 4). Eighty-five and one-tenth percent of indi-
viduals in urban areas had anti-HAV IgG while 95.9% of 
subjects in rural regions were anti-HAV IgG positive (p = 
0.001). Ninety-six and three-tenth percent of subjects had 
access to adequate treated water while 3.7% used untreat-
ed water (Table 4). Seroprevalence of anti-HAV antibody 
stratified by the number of family members is shown in 
Table 4—the higher the number of family members, the 
higher the seroprevalence of HAV (p = 0.001).
Discussion
In this cross-sectional study, we investigated the sero-
prevalence of HAV among adults from three cities of Fars 
province, southern Iran. HAV is highly prevalent in Fars 
province. We found an overall seroprevalence of 88.2% in 
our population which is nearly similar to reports from 
other parts of Iran (8, 9). Among these cities, Mamasani 
had the highest prevalence of HAV antibody (95.9%) that 
can be justified by the higher percentage of rural popu-
lation in this city compared to the two other cities. This 
pattern preserved in Shiraz and Abadeh, that is, Abadeh 
with  the  lowest  rural  population  had  the  lowest  HAV 
seroprevalence. As expected, the prevalence of HAV was 
higher in old ages; the rate reached to 99% in participants 
> 30 years. We also determined the seroprevalence of HAV 
in five groups of education. The serprevalence of HAV an-
tibody was lower in participants with higher educations 
(Table 4); the rate was 100% in uneducated peoples. Older 
age, residing in rural areas, numbers of family members 
were risk factors for HAV infection. One Iranian study 
reported a higher prevalence of HAV among older sub-
jects and in urban areas (9). The overall seroprevalence 
of HAV was 86% in this study. The seroprevalence of HAV 
was 22.3% among children in Tehran (capital of Iran) hos-
pitals. This study reported gradual rise in HAV seropreva-
lence in older ages (10). Another study showed that the 
seroprevalence of HAV in patients with chronic hepatitis 
B infection was 82.1%, which is similar to healthy popula-
tion (11). A cross-sectional study conducted in Bangladesh 
reported a seroprvalence rate of 69.6 % in Bangladeshi 
population. Older ages, rural areas and lower socioeco-
nomic status were risk factors for HAV infection (12). Our 
finding about association of age with seroprevalence of 
HAV antibody is concordant with results of other stud-
ies in developing countries, especially Asian countries 
(13, 14). Other studies in Asian population also showed a 
higher prevalence of HAV antibody in rural regions com-
pared to urban areas (15-17). Urban populations usually 
have better access to treated water and other sanitary 
services, higher socioeconomic status and lower number 
of family members.
In conclusion, according to results of this study, vacci-
nation against HAV may be helpful in adults in younger 
age  groups  and  people  from  urban  areas.  However,  it 
is not justified in rural areas since most of adults were 
infected during childhood and are immunized against 
HAV. More studies on cost-effectiveness and other aspects 
of HAV vaccination must be conducted for better assess-
ment of its benefits.
Negative No. (%) Positive No. (%)
Sex
Male
Female
44 (8.4%)
79 (14.9%)
479 (91.6%)
448 (85.1%)
Education
Uneducated
Preliminary
High school
Diploma
Post-diploma
0 (0%)
13 (7.2%)
3 (10.3%)
70 (11.9%)
30 (12.5%)
10 (100%)
169 (92.8%)
260 (89.7%)
518 (88.1%)
211 (87.5%)
Type of Residence
Urbant
Rural
109 (14.9%)
13 (4.1%)
620 (85.1%)
308 (95.9%) 
Job
Unemployed/Household
Worker
Clerk
Others
55 (14.8%)
3 (3.85%)
16 (11.6%)
32 (6.9%)
316 (85.2%) 
77 (96.2%)
122 (88.4%)
429 (93.1%) 
Treated water
Yes
No
120 (11.8%)
2 (5.2%)
892 (88.2%) 
36 (94.8%)
Family members
< 4
4–6
> 6
33 (19.9%)
51 (11.6%)
34 (7.6%)
133 (80.1%)
386 (88.4%) 
413 (92.4%)
Table 4. Seroprevalence of anti-HAV antibody according to sex, level of educa-
tion, type of residence, jobs, water access and numbers of family memberHepat Mon. 2011;11(4):285-288
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